Somryst

Sigurjon Kristjansson, CEO of Nox Health
Q&A: Nox Health on its $3.9M bid for Pear Therapeutics' assets
By Jessica Hagen | 12:27 pm | June 02, 2023
Sigurjon Kristjansson, CEO of Nox Health, tells MobiHealthNews why his company made the largest bid for Pear Therapeutics' assets at a recent bankruptcy auction
Pear's Somryst precursor improved sleep health measures among patients with chronic insomnia and depressive symptoms
By Dave Muoio | 02:40 pm | August 31, 2020
The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.
Pear Therapeutics kicks off decentralized digital therapeutic study, researchers envision drawn-on electronic sensors and more digital health news briefs
By Dave Muoio | 03:24 pm | July 14, 2020
Also: Google promises not to use Fitbit data for targeted advertising; Renalytix AI details its international IPO; New food tracking app relies on machine learning.
Q&A: A firsthand account of FDA's Pre-Cert Program
By Dave Muoio | 02:55 pm | March 27, 2020
Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.
FDA clears Pear's digital insomnia therapeutic through 510(k), Pre-Cert pilot pathways
By Dave Muoio | 04:53 pm | March 26, 2020
Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces.